Search results for "VIRUS DISEASE"

showing 10 items of 1907 documents

Cutaneous and Allergic reactions due to COVID‐19 vaccinations: A review

2021

ABSTRACT Introduction The pandemic caused by the novel coronavirus disease 2019 (COVID‐19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable strategy to end the pandemic, despite the slower‐than‐hoped‐for rollout, particularly for low‐to‐middle‐income countries, and the uncertain duration of protection afforded by vaccination. The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS‐CoV‐2 vaccines. This protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to Acute R…

medicine.medical_specialtyAllergyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)ExacerbationReview ArticleDermatologyallergic reactionsmedicine.disease_causeSARS‐CoV‐2VirusAntigenCOVID‐19PandemicHypersensitivityHumansMedicineIntensive care medicineReview ArticlesCoronavirusbusiness.industryVaccinationCOVID-19cutaneous reactionsmedicine.diseaseVaccinationBNT162b2mRNA VaccinesbusinessJournal of Cosmetic Dermatology
researchProduct

Prevalence of ulcerative stomatitis in arbovirus infections in a Brazilian Northeast population

2020

Background Although there are no population-based studies that support an association, there are reports in the literature of mucocutaneous, vesiculobullous and ulcerated lesions in the oral mucosa in cases of arbovirus infection. The aim of this study is to analyze the prevalence of ulcerative stomatitis in individuals affected by arboviruses in a population of the municipality of Arcoverde, Pernambuco, Brazil. Material and Methods 1,003 people living in an area assigned to a Primary Health Care Unit were interviewed. A structured questionnaire was used for data collection, with questions about sociodemographic variables, residence conditions, general health information, as well as informa…

medicine.medical_specialtyArbovirus InfectionsArbovirus infectionsvirusesMucocutaneous zonePopulationArbovirus Infectionsmedicine.disease_causeArbovirusDengue feverZika virusDengue03 medical and health sciences0302 clinical medicineUlcerative StomatitismedicinePrevalenceHumansChikungunyaOral mucosaeducationGeneral DentistryChikungunya fevereducation.field_of_studyOral Medicine and Pathologybusiness.industryResearchvirus diseases030206 dentistrybiochemical phenomena metabolism and nutrition:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDermatologymedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASChikungunya FeverSurgerybusinessArbovirusesBrazil
researchProduct

The implementation of pre-exposure prophylaxis in Spain without women

2018

El objetivo del presente artículo es la exposición sucinta de la exclusión de las mujeres en la resolución del 27 de Julio de 2017 en el que se explicita el convenio de colaboración entre la Dirección General de Salud Pública, Calidad e Innovación y la empresa Gilead Servicios S.L.U. Este convenio es la formalización de la entrada e implementación de la profilaxis preexposición ante el VIH en el territorio nacional. La profilaxis preexposición ante el VIH es una novedosa intervención biomédica de carácter preventivo aplicada en personas que no viven con el VIH, que contiene como parte fundamental la ingesta diaria de un medicamento llamado Truvada, formado por dos componentes farmacológicos…

medicine.medical_specialtyBiomedical interventionTenofovirDaily intakebusiness.industryPublic healthPreventionHuman immunodeficiency virus (HIV)virus diseasesVIHHIVExclusionMujeresEmtricitabinemedicine.disease_causeExclusiónPrePPrevenciónNursingMedicineWomenbusinessmedicine.drug
researchProduct

Does the use of face masks during the COVID-19 pandemic impact on oral hygiene habits, oral conditions, reasons to seek dental care and esthetic conc…

2021

Background To evaluate the impact of the use of face masks on oral hygiene habits; oral conditions self-perception; reasons to seek dental treatment; and esthetic concerns. Material and methods 1346 participants answered a web-based survey with questions related to the aims of the study. Descriptive statistic was performed and the responses were analyzed with chi-square test and regression analysis. Results With the use of masks, toothbrushing frequency decreased significantly, and people are significantly less concerned about oral hygiene. The number of subjects that reported to have halitosis increased significantly and this was associated with a decrease in toothbrushing frequency. The g…

medicine.medical_specialtyCOMPORTAMENTOCoronavirus disease 2019 (COVID-19)Descriptive statisticsbusiness.industryResearchDental health030206 dentistryDental careOral hygieneCommunity and Preventive DentistryTest (assessment)Face masksstomatognathic diseases03 medical and health sciences0302 clinical medicineFamily medicinePandemicMedicinebusinessGeneral DentistryUNESCO:CIENCIAS MÉDICAS030217 neurology & neurosurgery
researchProduct

High flow nasal therapy in Acute Exacerbation of COPD: Ready for the prime time?

2021

medicine.medical_specialtyCOPD2019-20 coronavirus outbreakNoninvasive VentilationExacerbationCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Oxygen Inhalation TherapyPulmonary diseaseGeneral Medicinemedicine.diseasePulmonary Disease Chronic ObstructiveEmergency MedicineCOPDHumansMedicineNoninvasive ventilationbusinessIntensive care medicineHigh flowThe American Journal of Emergency Medicine
researchProduct

Appendectomy during the COVID-19 pandemic in Italy: a multicenter ambispective cohort study by the Italian Society of Endoscopic Surgery and new tech…

2021

AbstractMajor surgical societies advised using non-operative management of appendicitis and suggested against laparoscopy during the COVID-19 pandemic. The hypothesis is that a significant reduction in the number of emergent appendectomies was observed during the pandemic, restricted to complex cases. The study aimed to analyse emergent surgical appendectomies during pandemic on a national basis and compare it to the same period of the previous year. This is a multicentre, retrospective, observational study investigating the outcomes of patients undergoing emergent appendectomy in March–April 2019 vs March–April 2020. The primary outcome was the number of appendectomies performed, classifie…

medicine.medical_specialtyCOVID-19 PandemicCoronavirus disease 2019 (COVID-19)Endoscopic surgeryNOAppendectomy; Appendicitis; COVID-19 Pandemic; Machine learningCohort Studies03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRetrospective StudiePandemicMachine learningmedicineHumansAppendectomyAppendicitiLaparoscopyPandemicsRetrospective Studiesmedicine.diagnostic_testPandemicbusiness.industryCOVID-19 Pandemic Appendicitis Appendicectomy Machine learningSARS-CoV-2COVID-19Length of Staymedicine.diseaseAppendicitisAppendicitisSettore MED/18SurgeryItaly030220 oncology & carcinogenesisAppendectomy; appendicitis; COVID-19 pandemic; machine learning; appendectomy; cohort studies; humans; Italy; length of stay; pandemics; postoperative complications; retrospective studies; SARS-CoV-2; appendicitis; COVID-19; laparoscopy030211 gastroenterology & hepatologySurgeryObservational studyOriginal ArticleLaparoscopyPostoperative ComplicationAppendicectomyCohort StudiebusinessComplicationCohort studyHuman
researchProduct

SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect?

2021

Since the dramatic rise of the coronavirus infection disease 2019 (COVID-19) pandemic, patients receiving dialysis have emerged as especially susceptible to this infection because of their impaired immunologic state, chronic inflammation and the high incidence of comorbidities. Although several strategies have thus been implemented to minimize the risk of transmission and acquisition in this population worldwide, the reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence varies across studies but is higher than in the general population. On the contrary, the screening for hepatitis viruses (HBV and HCV) has seen significant improvements in recent years, with va…

medicine.medical_specialtyCOVID19Health Toxicology and Mutagenesismedicine.medical_treatmentPopulation030232 urology & nephrologymedicine.disease_cause03 medical and health sciences0302 clinical medicineRenal DialysisSeroepidemiologic StudiesPandemicHepatitis VirusesmedicineSeroprevalenceHumanshepatitisIntensive care medicineeducationCoronavirusHepatitiseducation.field_of_studybusiness.industryTransmission (medicine)SARS-CoV-2RPublic Health Environmental and Occupational Healthvirus diseasesCOVID-19medicine.diseaseVaccinationEditorialMedicinedialysis030211 gastroenterology & hepatologyHemodialysisbusinesschronic kidney diseaseInternational Journal of Environmental Research and Public Health
researchProduct

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

2011

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in th…

medicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsPolymorphism Single NucleotideFlaviviridaeInternal medicineGenotypeEpidemiologyRibavirinmedicineHumansClinical Trials as TopicHepatologybiologybusiness.industryInterleukinsLiver Neoplasmsvirus diseasesHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsLiver TransplantationNatural historyHepatocellular carcinomaInterferon Type IPractice Guidelines as TopicHCVInterferonsbusiness
researchProduct

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepati…

2004

Introduction: In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon α-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon α-2b plus ribavirin, but it is still unproven whether this increase is cost effective. The objective of this study was to determine if the gain in SVR with peginterferon α-2a plus ribavirin is worth the incremental cost. Methods: We constructed a Markov model of disease progression in which cohorts of patients received peginterferon α-2a plus ribavirin or interferon α-2b plus ribavirin for 48 weeks (hepatitis C virus [HCV] genotype 1 and non-1 patients with fibrosis) or 24 weeks (genot…

medicine.medical_specialtyCirrhosisGenotypeCost effectivenessCost-Benefit AnalysisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsSensitivity and SpecificityGastroenterologypeginterferon alpha2aPolyethylene Glycolschemistry.chemical_compoundchronic hepatitiInterferonInternal medicineRibavirinmedicineHumansRandomized Controlled Trials as Topicalpha2b interferonAntiviral AgentPharmacologybusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthInterferon-alphavirus diseasesHealth Care CostsHepatitis CHepatitis C Chronicmedicine.diseaseMarkov ChainsRecombinant Proteinsdigestive system diseasesModels EconomicTreatment OutcomechemistryImmunologyQuality of LifePeginterferon alfa-2bDrug Therapy CombinationbusinessPeginterferon alfa-2amedicine.drugPharmacoEconomics
researchProduct

Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review

2009

Recently several randomized trials involving exclusively HCV 2 and 3 patients have explored the possibility of reducing the duration of therapy with PEG IFNs and ribavirin to 12–16 weeks. Among these, the largest studies (ACCELERATE, NORTH-C and NORDynamIC) have failed to demonstrate, by intention-to-treat analysis, that short treatment is non-inferior to the standard duration of 24 weeks originated by phase 3 trials. Even though obtaining univocal conclusions from these studies are difficult to obtain due to some critical differences (trial design, genotypes 2/3 ratio, rate of cirrhosis at baseline, ribavirin dose, assays to detect HCV-RNA etc), all have proved that a rapid virological res…

medicine.medical_specialtyCirrhosisGenotypeHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundPharmacotherapyRandomized controlled triallawInterferonInternal medicineRibavirinmedicineHumansHepatologybusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseaseschemistryImmunologyDrug Therapy CombinationViral hepatitisbusinessmedicine.drugLiver International
researchProduct